Lauren Averett Byers, MD, MS
机构: MD Anderson Cancer Center
每年引用次数
引用次数
引用: 40,634
H-指数: 75
I10-指数 : 171
出版物: 489
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.
Lloyd T Lam , Oxana K Pickeral , Amy C Peng , Andreas Rosenwald
Genome Biology 2 ( 10) 1 -11
330
2001
Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition.
C. Allison Stewart , Lauren Averett Byers
Cancer Cell 28 ( 1) 4 -6
34
2015
Establishing role of KRAS mutation on NSCLC radio-sensitivity
Vikas Bhardwaj , Anna Likhacheva , Lauren A Byers A Byers , Lixia Diao
Cancer Research 72 ( 8_Supplement) 3454 -3454
2012
Molecular subtyping of small cell lung cancer to predict therapeutic responses
Lauren A BYERS , John V HEYMACH
2
2023
Molecular subtyping of small cell lung cancer to predict therapeutic responses
Lauren A BYERS , John V HEYMACH
2024
Mapping therapy resistant phenotypes in SCLC liquid biopsies with single-cell proteomics at a personalized level
Sayantan BHATTACHARYYA , Catherine A STEWART , Ashley M VICTORIAN , Shafqat F EHSAN
AMER ASSOC CANCER RESEARCH
2023
Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients.
Guangchun Han , Ansam Sinjab , Kieko Hara , Warapen Treekitkarnmongkol
Cancers 13 ( 6) 1250
2021
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M Rudin , M Catherine Pietanza , Todd M Bauer , Neal Ready
The Lancet Oncology 18 ( 1) 42 -51
425
2017
Assessing the clinical utility of cancer genomic and proteomic data across tumor types
Gad Getz , Han Liang , Yuan Yuan , Eliezer M Van Allen
Nature Biotechnology 32 ( 7) 644 -652
290
2014
Abstract A096: LKB1 deficiency and KEAP1/NRF2 pathway alterations as biomarkers of response for ATR and ATM inhibitors and other inhibitors of DNA damage response (DDR) in NSCLC
Ana Galan-Cobo , Marlese Pisegna , Kavya Ramkumar , Alissa Poteete
Molecular Cancer Therapeutics 18
2019
Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non--Small-Cell Lung Cancer Data Set
Stephanie T Schmidt , Neal Akhave , Ryan E Knightly , Alexandre Reuben
JCO Clinical Cancer Informatics 6 e2200040
2022
Single-cell analyses reveal increasing intratumoral heterogeneity as an essential component of treatment resistance in small cell lung cancer
C Allison Stewart , Carl M Gay , Yuanxin Xi , Junya Fujimoto
Cancer Research 79 ( 13\_Supplement) 2899 -2899
2
2019
Paired, single-cell profiling of circulating tumor cell-derived xenograft models of small cell lung cancer reveals intratumoral heterogeneity and emergence of new cell clusters following treatment relapse
C Allison Stewart , Carl M Gay , Yuanxin Xi , Santhosh Sivajothi
Cancer Research 80 ( 16\_Supplement) 1496 -1496
2020
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Yasir Y Elamin , Jacqulyne P Robichaux , Brett W Carter , Mehmet Altan
Cancer Cell 40 ( 7) 754 -767
9
2022
Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma
Runzhe Chen , Jun Li , Junya Fujimoto , Lingzhi Hong
Journal of Experimental \& Clinical Cancer Research 41 ( 1) 1 -13
1
2022
Home Evolving Standards of Care Biomarkers May Illuminate the Path Forward for PARP Inhibitors in SCLC
Marcelo V Negrao , Lauren A Byers , Carl M Gay
Smpte Journal
SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer
Kiran Kundu , Robert J Cardnell , Bingnan Zhang , Li Shen
Translational Lung Cancer Research 10 ( 11) 4095
9
2021
Multiplex immunofluorescence (mIF) reveals differences in tumor immune microenvironment between molecularly-defined subsets of small cell lung cancer
Pedro Rocha , C Allison Stewart , Edwin Parra , Luisa M Solis
Cancer Research 81 ( 13\_Supplement) 2758 -2758
2021
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control
Kyle Concannon , Benjamin B Morris , Carl M Gay , Lauren A Byers
Molecular cell
2023
Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial
Yufei Liu , Luyang Yao , Neda Kalhor , Brett W Carter
Lung Cancer 174 112 -117
2022